Abstract:Despite a growing number of effective therapeutic options for patients with pancreatic adenocarcinoma, the prognosis remains dismal mostly due to the late-stage presentation and spread of the cancer to other organs. Because a genomic analysis of pancreas tissue revealed that it may take years, if not decades, for pancreatic cancer to develop, we performed radiomics and fat fraction analysis on contrast-enhanced CT (CECT) scans of patients with historical scans showing no evidence of cancer but who subsequently went on to develop pancreas cancer years later, in an attempt to identify specific imaging features of the normal pancreas that may portend the subsequent development of the cancer. In this IRB-exempt, retrospective, single institution study, CECT chest, abdomen, and pelvis (CAP) scans of 22 patients who had evaluable historical imaging data were analyzed. The images from the "healthy" pancreas were obtained between 3.8 and 13.9 years before the diagnosis of pancreas cancer was established. Afterwards, the images were used to divide and draw seven regions of interest (ROIs) around the pancreas (uncinate, head, neck-genu, body (proximal, middle, and distal) and tail). Radiomic analysis on these pancreatic ROIs consisted of first order quantitative texture analysis features such as kurtosis, skewness, and fat quantification. Of all the variables tested, fat fraction in the pancreas tail (p = 0.029) and asymmetry of the histogram frequency curve (skewness) of pancreas tissue (p = 0.038) were identified as the most important imaging signatures for subsequent cancer development. Changes in the texture of the pancreas as measured on the CECT of patients who developed pancreas cancer years later could be identified, confirming the utility of radiomics-based imaging as a potential predictor of oncologic outcomes. Such findings may be potentially useful in the future to screen patients for pancreatic cancer, thereby helping detect pancreas cancer at an early stage and improving survival.

Radiology of pancreatic adenocarcinoma: Current status of imaging

Accurate imaging diagnosis and evaluation of pancreatic cancer

Imaging diagnosis of pancreatic cancer and preoperative imaging evaluation of resectability and staging

Imaging of Pancreatic Adenocarcinoma: Update on Staging/Resectability

Molecular Imaging of Pancreatic Ductal Adenocarcinoma

Imaging of Pancreatic Ductal Adenocarcinoma: An Update on Recent Advances

Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review

CT Imaging Assessment of Pancreatic Adenocarcinoma Resectability after Neoadjuvant Therapy: Current Status and Perspective on the Use of Radiomics

Imaging Modalities for Early Detection of Pancreatic Cancer: Current State and Future Research Opportunities

Imaging for Early Detection of Pancreatic Ductal Adenocarcinoma: Updates and Challenges in the Implementation of Screening and Surveillance Programs

An update on pancreatic cancer imaging, staging and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment

Pancreatic Ductal Adenocarcinoma: Update of CT-Based Radiomics Applications in the Pre-Surgical Prediction of the Risk of Post-Operative Fistula, Resectability Status and Prognosis

Landmarks in pancreatic cancer studies

Can Imaging Using Radiomics and Fat Fraction Analysis Detect Early Tissue Changes on Historical CT Scans in the Regions of the Pancreas Gland That Subsequently Develop Adenocarcinoma?

Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma

Indications for Radiation in Pancreatic Adenocarcinoma: A Review

Position Emission Tomography Imaging in Pancreatic Cancer: Recent Progress and Future Directions

Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer

Role Of Imaging In Evaluating The Response After Neoadjuvant Treatment For Pancreatic Ductal Adenocarcinoma

Role of Endoscopic Ultrasound in Diagnosis of Pancreatic Ductal Adenocarcinoma

Role of imaging in the applicability of irreversible electroporation for the management of pancreatic adenocarcinoma